Quick Takeaways Retatrutide is a triple-receptor agonist (GLP-1, GIP, glucagon) delivering superior monotherapy weight loss at 2428.7% over 4868 weeks Cagrilintide targets amylin receptors for satiety and gastric emptying, achieving 10.8% weight loss in 26 weeks as a monotherapy Retatrutide provides broader metabolic benefits, including dramatic improvements in HbA1c, blood pressure, waist circumference, insulin sensitivity, and liver fat normalization No head-to-head trials exist yet, but the mechanistic and clinical data strongly favor Retatrutide for total body recomposition Retatrutide vs Cagrilintide: Side-by-Side Comparison What Makes Retatrutide Different Retatrutide isnt just another GLP-1 receptor agonist
Significant main effects of treatment group (prior to BenjaminiHochberg correction since none were significant after correction, although the necessity of correction for multiple comparisons in exploratory analyses remains unresolved 49 ) were observed for the unclassified group and ten classified genera, namely, Acetatifactor , Akkermansia , Erysipelatoclostridium , [ Eubacterium ] coprostanoligenes group , Family XIII UCG-001 , Lactobacillus , Parasutterella , Ruminiclostridium 6 , Ruminococcaceae UCG-004 , and Ruminococcaceae UCG-009
Additional ingredients can have a functional purpose
& Horak, F
